Physician profile
Eric Gershman
NPI 1316903768
$29,175.77
in general payments reported to CMS, 2019-2025
65 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,434 · 2020: $5,118 · 2021: $1,749 · 2022: $10K · 2023: $874 · 2024: $4,300 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080 · Consulting Fee: $3,035 · Education: $251 · Travel and Lodging: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,080.41 |
| Consulting Fee | $3,035.00 |
| Education | $251.19 |
| Travel and Lodging | $244.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,628.85 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Servier Pharmaceuticals LLC | $4,518.46 | 2022 | |
| Pfizer INC. | $3,519.06 | 2019-2025 | |
| Beigene USA, INC. | $1,925.00 | 2024 | Brukinsa |
| Amgen INC. | $1,115.03 | 2019-2022 | |
| Beigene, Ltd. | $975.00 | 2020-2021 | |
| Incyte Corporation | $893.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $815.09 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $777.77 | 2019-2025 | Reblozyl, Opdivo |
| Regeneron Healthcare Solutions, INC. | $701.17 | 2019-2025 | Libtayo |
| Seagen INC. | $546.96 | 2019-2022 | |
| Daiichi Sankyo INC. | $523.65 | 2019-2025 | Datroway, Enhertu |
| Janssen Biotech, INC. | $451.62 | 2019-2025 | Erleada, Imbruvica, Rybrevant |
| Genzyme Corporation | $406.80 | 2019-2025 | |
| Foundation Medicine, INC. | $343.17 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gershman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.